[1] Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer's disease[J]. Lancet, 2021, 397:1577-1590. [2] Benenati S, Canale C, De Marzo V, Della Bona R, Rosa GM, Porto I. Atrial fibrillation and Alzheimer's disease:a conundrum[J]. Eur J Clin Invest, 2021, 51:e13451. [3] GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018, 392:1789-1858. [4] Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Ferguson JF, Generoso G, Ho JE, Kalani R, Khan SS, Kissela BM, Knutson KL, Levine DA, Lewis TT, Liu J, Loop MS, Ma J, Mussolino ME, Navaneethan SD, Perak AM, Poudel R, Rezk-Hanna M, Roth GA, Schroeder EB, Shah SH, Thacker EL, VanWagner LB, Virani SS, Voecks JH, Wang NY, Yaffe K, Martin SS. Heart disease and stroke statistics-2022 update:a report from the American Heart Association[J]. Circulation, 2022, 145:e153-639. [5] Yang M, Li C, Zhang Y, Ren J. Interrelationship between Alzheimer's disease and cardiac dysfunction:the brain-heart continuum[J]? Acta Biochim Biophys Sin (Shanghai), 2020, 52:1-8. [6] Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease[J]. Mol Neurodegener, 2020, 15:40. [7] Kuo YM, Kokjohn TA, Watson MD, Woods AS, Cotter RJ, Sue LI, Kalback WM, Emmerling MR, Beach TG, Roher AE. Elevated Aβ42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AβPP metabolism[J]. Am J Pathol, 2000, 156:797-805. [8] Troncone L, Luciani M, Coggins M, Wilker EH, Ho CY, Codispoti KE, Frosch MP, Kayed R, Del Monte F. Aβ amyloid pathology affects the hearts of patients with Alzheimer's disease:mind the heart[J]. J Am Coll Cardiol, 2016, 68:2395-2407. [9] McLendon PM, Robbins J. Proteotoxicity and cardiac dysfunction[J]. Circ Res, 2015, 116:1863-1882. [10] Gonzalez-Garcia M, Fusco G, De Simone A. Membrane interactions and toxicity by misfolded protein oligomers[J]. Front Cell Dev Biol, 2021, 9:642623. [11] Jensen BC, Willis MS. The head and the heart:the Alzheimer's connection[J]. J Am Coll Cardiol, 2016, 68:2408-2411. [12] Sanna GD, Nusdeo G, Piras MR, Forteleoni A, Murru MR, Saba PS, Dore S, Sotgiu G, Parodi G, Ganau A. Cardiac abnormalities in Alzheimer disease:clinical relevance beyond pathophysiological rationale and instrumental findings[J]? JACC Heart Fail, 2019, 7:121-128. [13] Liu Y, Subedi K, Baride A, Romanova S, Callegari E, Huber CC, Wang X, Wang H. Peripherally misfolded proteins exacerbate ischemic stroke-induced neuroinflammation and brain injury[J]. J Neuroinflammation, 2021, 18:29. [14] Ranek MJ, Bhuiyan MS, Wang X. Editorial:targeting cardiac proteotoxicity[J]. Front Physiol, 2021, 12:669356. AJ. [15] Alawode DOT, Fox NC, Zetterberg H, Heslegrave Alzheimer's disease biomarkers revisited from the amyloid cascade hypothesis standpoint[J]. Front Neurosci, 2022, 16:837390. [16] Saez-Atienzar S, Masliah E. Cellular senescence and Alzheimer disease:the egg and the chicken scenario[J]. Nat Rev Neurosci, 2020, 21:433-444. [17] Morrone CD, Bishay J, McLaurin J. Potential role of venular amyloid in Alzheimer's disease pathogenesis[J]. Int J Mol Sci, 2020, 21:1985. and Alzheimer's disease [18] Liu RM. Aging, cellular senescence,[J]. Int J Mol Sci, 2022, 23:1989. [19] Mussinelli R, Salinaro F, Alogna A, Boldrini M, Raimondi A, Musca F, Palladini G, Merlini G, Perlini S. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis[J]. Ann Noninvasive Electrocardiol, 2013, 18:271-280. M, [20] Murphy J, Le TNV, Fedorova J, Yang Y, Krause-Hauch Davitt K, Zoungrana LI, Fatmi MK, Lesnefsky EJ, Li J, Ren D. The cardiac dysfunction caused by metabolic alterations in Alzheimer's disease[J]. Front Cardiovasc Med, 2022, 9:850538. [21] Wolters FJ, Hilal S, Leening MJG, Kavousi M, Ghanbari M, Franco OH, Hofman A, Koudstaal PJ, Vernooij MW, Ikram MK, Bos D, Ikram MA; Heart Brain Connection Consortium. Plasma amyloid-β40 in relation to subclinical atherosclerosis and cardiovascular disease:a population-based study[J]. Atherosclerosis, 2022, 348:44-50. [22] Hjelm C, Broström A, Dahl A, Johansson B, Fredrikson M, Strömberg A. Factors associated with increased risk for dementia in individuals age 80 years or older with congestive heart failure[J]. J Cardiovasc Nurs, 2014, 29:82-90. [23] Andrade-Guerrero J, Santiago-Balmaseda A, Jeronimo-Aguilar P, Vargas-Rodríguez I, Cadena-Suárez AR, Sánchez-Garibay C, Pozo-Molina G, Méndez-Catalá CF, Cardenas-Aguayo MD, Diaz-Cintra S, Pacheco-Herrero M, Luna-Muñoz J, Soto-Rojas LO. Alzheimer's disease:an updated overview of its genetics[J]. Int J Mol Sci, 2023, 24:3754. George-Hyslop [24] Saunders AM, Strittmatter WJ, Schmechel D, PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease[J]. Neurology, 1993, 43:1467-1472. [25] Li H, Chen Y, Zhou B, Peng Y, Sheng Y, Rao L. Polymorphisms of presenilin-1 gene associate with dilated cardiomyopathy susceptibility[J]. Mol Cell Biochem, 2011, 358:31-36. Das S, Hyman BT. APOE and Alzheimer's [26] Serrano-Pozo A, disease:advances in genetics, pathophysiology, and therapeutic approaches[J]. Lancet Neurol, 2021, 20:68-80. [27] Alata W, Ye Y, St-Amour I, Vandal M, Calon F. Human apolipoprotein E ε4 expression impairs cerebral vascularization and blood-brain barrier function in mice[J]. J Cereb Blood Flow Metab, 2015, 35:86-94. [28] Bown CW, Liu D, Osborn KE, Gupta DK, Mendes LA, Pechman KR, Hohman TJ, Wang TJ, Gifford KA, Jefferson AL. Apolipoprotein E genotype modifies the association between cardiac output and cognition in older adults[J]. J Am Heart Assoc, 2019, 8:e011146. [29] Metin Ö, Tufan AE, Cevher Binici N, Saraçlı Ö, Atalay A, Yolga Tahiroğlu A. Executive functions in frontal lob syndrome:a case report[J]. Turk Psikiyatri Derg, 2017, 28:135-138. [30] Bagaria J, Bagyinszky E, An SSA. Genetics, functions, and clinical impact of presenilin-1(PSEN1) gene[J]. Int J Mol Sci, 2022, 23:10970. [31] Li D, Parks SB, Kushner JD, Nauman D, Burgess D, Ludwigsen S, Partain J, Nixon RR, Allen CN, Irwin RP, Jakobs PM, Litt M, Hershberger RE. Mutations of presenilin genes in dilated cardiomyopathy and heart failure[J]. Am J Hum Genet, 2006, 79:1030-1039. [32] Pizzo P, Basso E, Filadi R, Greotti E, Leparulo A, Pendin D, Redolfi N, Rossini M, Vajente N, Pozzan T, Fasolato C. Presenilin-2 and calcium handling:molecules, organelles, cells and brain networks[J]. Cells, 2020, 9:2166. [33] Gianni D, Li A, Tesco G, McKay KM, Moore J, Raygor K, Rota M, Gwathmey JK, Dec GW, Aretz T, Leri A, Semigran MJ, Anversa P, Macgillivray TE, Tanzi RE, del Monte F. Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy[J]. Circulation, 2010, 121:1216-1226. [34] Khan S, Barve KH, Kumar MS. Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease[J]. Curr Neuropharmacol, 2020, 18:1106-1125. [35] Milionis HJ, Florentin M, Giannopoulos S. Metabolic syndrome and Alzheimer's disease:a link to a vascular hypothesis[J]? CNS Spectr, 2008, 13:606-613. [36] Fisher RA, Miners JS, Love S. Pathological changes within the cerebral vasculature in Alzheimer's disease:new perspectives[J]. Brain Pathol, 2022, 32:e13061. [37] Kim HW, Hong J, Jeon JC. Cerebral small vessel disease and Alzheimer's disease:a review[J]. Front Neurol, 2020, 11:927. [38] Sauvé MJ, Lewis WR, Blankenbiller M, Rickabaugh B, Pressler SJ. Cognitive impairments in chronic heart failure:a case controlled study[J]. J Card Fail, 2009, 15:1-10. [39] Jin WS, Bu XL, Wang YR, Li L, Li WW, Liu YH, Zhu C, Yao XQ, Chen Y, Gao CY, Zhang T, Zhou HD, Zeng F, Wang YJ. Reduced cardiovascular functions in patients with Alzheimer's disease[J]. J Alzheimers Dis, 2017, 58:919-925. [40] Kurz C, Walker L, Rauchmann BS, Perneczky R. Dysfunction of the blood-brain barrier in Alzheimer's disease:evidence from human studies[J]. Neuropathol Appl Neurobiol, 2022, 48:e12782. [41] Tai XY, Veldsman M, Lyall DM, Littlejohns TJ, Langa KM, Husain M, Ranson J, Llewellyn DJ. Cardiometabolic multimorbidity, genetic risk, and dementia:a prospective cohort study[J]. Lancet Healthy Longev, 2022, 3:e428-436. |